Sorry, you need to enable JavaScript to visit this website.

ELEVATE UC 12: Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis

ELEVATE UC 12: Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis.

Category & Conditions: Immune System Diseases and Conditions
Medicine: ETRASIMOD
ClinicalTrials.gov Identifier (NCT): NCT03996369
Protocol ID: APD334-302
    Share
PrintDownload
Open Plain Language Summary Result: Click here